George Hodgin

Cancer treatment and research center City of Hope and Biopharmaceutical Research Company, a pharmaceutical company that specializes in the development of proprietary cannabinoid therapeutics, announced on Thursday that the first patient has received BRC-001, an experimental supportive care therapy...

The Biopharmaceutical Research Company (BRC), an active DEA pharmaceutical cannabis license holder, announced the completion of a $20 million Series A fundraise, that will enable the company to scale its operations and increase its product offering, conduct sponsored research, and execute...

Open Book Extracts (OBX) entered into a partnership with Biopharmaceutical Research Company (BRC). Under the terms of the collaboration, OBX will leverage BRC's research platforms, in order to develop research-backed formulations and products including Delta-9 THC. From preclinical and first-in...

The Drug Enforcement Administration (DEA) finally authorized two cannabis companies to harvest marijuana for research purposes, reported Marijuana Moment, ending a five-decade federal monopoly. Why is this important?  Because a farm functioning as part of the ...

Clever Leaves Holdings Inc. (NASDAQ: CLVR) confirmed Wednesday that it will export 30 kg of high-THC cannabis flower from its Portugal facility to the Biopharmaceutical Research Company (“BRC”), a DEA-licensed pharmaceutical company. BRC develops federally compliant active...

The Drug Enforcement Administration (DEA) announced on Friday that it will begin approving applications that will allow some cannabis growers to become federally authorized to manufacture the plant for research purposes, reported the Wall Street Journal. What Happened Though the DEA began...